Biobanks constitute foundational infrastructure for precision breast oncology, bridging discovery science and clinical implementation, and their capacity to integrate multi-omics datasets with functional tumor models positions them as essential drivers of individualized therapy.
Abstract
Introduction: Breast cancer exhibits marked biological heterogeneity that challenges conventional therapeutic strategies. Biobanks have emerged as critical infrastructures supporting precision oncology by integrating high-quality biospecimens with multidimensional molecular data, yet their current landscape and clinical impact remain incompletely characterized.
Objective: To systematically map the development, structure, and translational applications of breast cancer biobanks in precision medicine.
Methods: A scoping review was conducted using PubMed, Embase, Web of Science, and SciELO databases from 2019 to 2024. Eligible studies addressed biobank infrastructure, biospecimen management, and integration with clinical or genomic data. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Scoping Review (PRISMA-ScR) guidelines, 25 studies underwent qualitative synthesis.
Results: Contemporary biobanks have evolved into dynamic, interoperable platforms integrating tumor tissues, liquid biopsies, nucleic acids, and patient-derived organoids. These repositories enable comprehensive molecular profiling through next-generation sequencing, transcriptomics, and proteomics, facilitating biomarker discovery and therapeutic stratification. Integration with longitudinal clinical outcomes enhances predictive modeling for treatment response and resistance mechanisms. Key applications include the identification of actionable mutations, development of companion diagnostics, and validation of novel therapeutic targets. However, critical barriers persist: protocol heterogeneity that compromises data harmonization, limited interoperability across institutions, insufficient sustainable funding, and systematic underrepresentation of non-European populations. Ethical frameworks and regulatory standards remain inconsistent across jurisdictions, hindering international collaboration and data sharing.
Conclusion: Biobanks constitute foundational infrastructure for precision breast oncology, bridging discovery science and clinical implementation. Their capacity to integrate multi-omics datasets with functional tumor models positions them as essential drivers of individualized therapy. Realizing their full potential requires urgent prioritization of international standardization initiatives, equitable population representation, sustainable funding mechanisms, and harmonized ethical frameworks. These advances are critical to ensuring that precision medicine benefits reach diverse patient populations globally and translate into measurable improvements in clinical outcomes.
ABSTRACT Introduction Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide, with outcomes depending on the stages at diagnosis. Genomic and transcriptomic classifications are largely inferential because the genotype–phenotype relationship is non-linear and is influenced by post-translational r...
P. Ramachandran, C.-S.-Y. Chen, C. Lee et al.· Espert Review of Proteomics· 0 citations
Cancer precision medicine is moving beyond static, single-analyte profiling toward a dynamic view of tumour biology and treatment response. A multiomics approach, integrating genomic, transcriptomic, proteomic, metabolomic, and epigenomic information, offers a more comprehensive framework for understanding tumour heter...
H. Markiewicz, Aleksander Murawa, Zachariasz Rytelewski et al.· Pharmaceuticals· 0 citations
BACKGROUND
DNA methylation alterations are stable, biologically informative, and detectable in tissue and circulating DNA, making them promising biomarkers for non-small cell lung cancer (NSCLC). However, few methylation biomarkers have entered routine clinical practice. We aimed to characterize the evolution and trans...
Yun-Yi Li, Fang Wu, Wen-Liang Liu et al.· Epigenomics· 0 citations
Introduction: Breast cancer exhibits marked biological heterogeneity, resulting in variable responses to chemotherapy. The lack of accurate predictive biomarkers in clinical practice limits therapeutic personalization and exposes patients to unnecessary toxicities. In this context, circulating microRNAs (miRNAs) have e...
Júlia Vieira Lipert Pazzim, Daisy Crispym, Nathalia Cruz Costa et al.· Mastology· 0 citations
This review evaluates Mediator complex-related transcriptional programs as a candidate regulatory layer that may complement existing CRC biomarker frameworks and concludes that CRC biomarker development should integrate rather than replace complementary information layers.
The transition from single-gene testing to comprehensive genomic profiling (CGP) is essential for precision oncology. The next generation sequence platform, enables the simultaneous detection of diverse variants and complex immuno-oncology biomarkers, providing a holistic view of the tumor genomic landscape....
Chung-Gue Huang, Shu-Li Yang, Chang-Fu Kuo et al.· Clinical Chemistry· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.